Indaptus Therapeutics Inc INDP 深 滬
等待開盤 07-19 09:30:00 美东时间
11.60
+0.290
+2.56%
華盛通- 最 高12.00
- 今 開11.28
- 成交量 1.04万股
- 最 低 11.28
- 昨 收 11.31
- 總市值 1.86亿
- 52周最高 59.36
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.5628
- 委 比 97.22%
- 總股本 1603.44万
- 歷史最高 21952.00
- 量 比 1.14
- 振 幅 6.37%
- 歷史最低 7.5628
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 171.6% to $27....
07-07 20:07
Indaptus Therapeutics Raises $5.7M for R&D Initiatives
The latest update is out from Indaptus Therapeutics ( ($INDP) ). On June 12 and...
07-01 21:08
Indaptus Therapeutics to execute 1-for-28 reverse stock split
Indaptus Therapeutics (NASDAQ:INDP) has approved a 1-for-28 reverse stock split of its common stock, effective after trading closes on June 26, 2025. The stock split is intended to increase the per sh...
06-25 19:57
Indaptus Therapeutics Announces Reverse Stock Split
Indaptus Therapeutics董事会批准了1:28的反向股票分割，将于6月26日生效，交易调整于6月27日开始。股票代码保持不变，CUSIP变更为45339J 204。此次操作旨在提升股价以符合纳斯达克要求并吸引更多投资者。股东将不会收到零散股，零散股将获得现金补偿。股票数量将由1600万股减至57.2万股，托管股证持有者将自动处理。
06-25 11:00
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to c...
06-25 00:52
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
Shares of Sequans Communications S.A. (NYSE:SQNS) rose sharply in today's pre-m...
06-23 18:51
Indaptus Therapeutics Sells ~$2.3M In Aggregate Principal Amount Of Convertible Promissory Notes And Accompanying Warrants To Raise Up To $5M In Gross Proceeds
Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3
06-13 20:04
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics announced the sale of approximately $2.3 million in convertible promissory notes and warrants, with plans to raise up to $5 million. The notes bear 6% interest annually, mature in July 2026, and convert into shares at 80% of the average closing price over five days prior to conversion, capped at $0.40. Warrants for 200% of the conversion shares will be issued post-conversion. Proceeds will fund research, including a Phase 1b...
06-13 12:00
Indaptus Therapeutics Doses First Patient In Phase 1b/2 Trial Expansion Of Decoy20 Combo For Advanced Solid Tumors
Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the expansion
06-02 20:08
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics has initiated a new Phase 1b/2 clinical trial arm evaluating the combination of Decoy20 and Beigene’s PD-1 inhibitor, tislelizumab, in advanced solid tumor patients. This trial aims to assess safety, optimal dosing, and anti-tumor activity, particularly in patients who have not responded to checkpoint inhibitors or have tumor types typically unresponsive to such therapies. Decoy20 has shown synergistic effects with checkpoin...
06-02 12:00
